CDA | Evidence Driven
CDA | Evidence Driven

regorafenib

Details

Files
Generic Name:
regorafenib
Project Status:
Pending
Therapeutic Area:
Metastatic osteosarcoma
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0374-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
​Indicated for the treatment of metastatic osteosarcoma in patients who received at least 1 prior line of therapy.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.

Files

Proposed Scope View PDF
Last Updated : October 21, 2024